Multiple neuroprotective and anti-inflammatory pathway components

The term "Multiple neuroprotective and anti-inflammatory pathway components" is a descriptive classification used in pharmacological databases to characterize drugs with pleiotropic effects, most notably dimethyl fumarate [AdisInsight]. Rather than binding to a single receptor or enzyme, these agents modulate a network of pathways that collectively reduce inflammation and protect neural tissue [Link et al., 2013]. The most well-characterized component is the activation of the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which triggers the transcription of antioxidant genes to combat oxidative stress [FDA Tecfidera Label]. Simultaneously, these agents suppress pro-inflammatory signaling through the inhibition of Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [PubChem]. This dual action helps to mitigate the autoimmune-mediated demyelination and axonal loss observed in conditions such as multiple sclerosis [National MS Society]. Additionally, some components of this mechanism may involve the activation of the hydroxycarboxylic acid receptor 2 (HCAR2), which contributes to anti-inflammatory effects in the gut and immune system [Offermanns, 2014]. Because it encompasses a broad range of molecular interactions rather than a single protein, it is categorized as a pathway-based mechanism rather than a discrete therapeutic target. This holistic approach to neuroprotection is a hallmark of second-generation oral therapies for relapsing forms of multiple sclerosis.

Other names

Pleiotropic neuroprotective pathwaysNrf2-mediated antioxidant responseNF-kappaB inflammatory signaling modulation

Activation of the Nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant response pathway and inhibition of pro-inflammatory pathways such as Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) [FDA Tecfidera Label, PubChem].